Ocular Therapeutix annual revenue
2012
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ocular Therapeutix Revenue Growth & History (OCUL)
Ocular Therapeutix reported $52.0M in revenue for fiscal 2025, a decrease of 18.47% from the previous fiscal year.
View full Ocular Therapeutix company overviewOcular Therapeutix annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $52.0M | −$11.8M | −18.47% |
| 2024 | 2024-12-31 | $63.7M | $5.3M | +9.03% |
| 2023 | 2023-12-31 | $58.4M | $6.9M | +13.49% |
| 2022 | 2022-12-31 | $51.5M | $8.0M | +18.32% |
| 2021 | 2021-12-31 | $43.5M | $26.1M | +150.08% |
| 2020 | 2020-12-31 | $17.4M | $13.2M | +311.71% |
| 2019 | 2019-12-31 | $4.2M | $2.2M | +112.41% |
| 2018 | 2018-12-31 | $2.0M | $67,000 | +3.48% |
| 2017 | 2017-12-31 | $1.9M | $36,000 | +1.91% |
| 2016 | 2016-12-31 | $1.9M | $137,000 | +7.83% |
| 2015 | 2015-12-31 | $1.8M | $978,000 | +126.68% |
| 2014 | 2014-12-31 | $772,000 | — | — |
| 2012 | 2012-12-31 | $10,000 | — | — |
Ocular Therapeutix quarterly revenue
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $13.5M | $16,000 | +0.12% |
| Q1 2026 | 2026-03-31 | $10.8M | $87,000 | +0.81% |
| Q4 2025 | 2025-12-31 | $13.3M | −$3.8M | −22.44% |
| Q3 2025 | 2025-09-30 | $14.5M | −$881,000 | −5.71% |
| Q2 2025 | 2025-06-30 | $13.5M | −$3.0M | −18.14% |
| Q1 2025 | 2025-03-31 | $10.7M | −$4.1M | −27.59% |
| Q4 2024 | 2024-12-31 | $17.1M | $2.3M | +15.41% |
| Q3 2024 | 2024-09-30 | $15.4M | $344,000 | +2.28% |
| Q2 2024 | 2024-06-30 | $16.4M | $1.3M | +8.26% |
| Q1 2024 | 2024-03-31 | $14.8M | $1.4M | +10.47% |
| Q4 2023 | 2023-12-31 | $14.8M | $726,000 | +5.16% |
| Q3 2023 | 2023-09-30 | $15.1M | $3.1M | +26.04% |
| Q2 2023 | 2023-06-30 | $15.2M | $2.9M | +23.81% |
| Q1 2023 | 2023-03-31 | $13.4M | $187,000 | +1.42% |
| Q4 2022 | 2022-12-31 | $14.1M | $1.8M | +14.36% |
| Q3 2022 | 2022-09-30 | $12.0M | −$188,000 | −1.55% |
| Q2 2022 | 2022-06-30 | $12.3M | $548,000 | +4.68% |
| Q1 2022 | 2022-03-31 | $13.2M | $5.8M | +79.61% |
| Q4 2021 | 2021-12-31 | $12.3M | $5.0M | +67.49% |
| Q3 2021 | 2021-09-30 | $12.2M | $6.3M | +106.82% |
| Q2 2021 | 2021-06-30 | $11.7M | $10.1M | +646.85% |
| Q1 2021 | 2021-03-31 | $7.3M | $4.7M | +181.41% |
| Q4 2020 | 2020-12-31 | $7.3M | $5.1M | +225.75% |
| Q3 2020 | 2020-09-30 | $5.9M | $5.0M | +608.81% |
| Q2 2020 | 2020-06-30 | $1.6M | $919,000 | +141.38% |
| Q1 2020 | 2020-03-31 | $2.6M | $2.1M | +430.28% |
| Q4 2019 | 2019-12-31 | $2.3M | $1.8M | +347.62% |
| Q3 2019 | 2019-09-30 | $829,000 | $331,000 | +66.47% |
| Q2 2019 | 2019-06-30 | $650,000 | $2,000 | +0.31% |
| Q1 2019 | 2019-03-31 | $492,000 | $152,000 | +44.71% |
| Q4 2018 | 2018-12-31 | $504,000 | $17,000 | +3.49% |
| Q3 2018 | 2018-09-30 | $498,000 | −$25,000 | −4.78% |
| Q2 2018 | 2018-06-30 | $648,000 | $210,000 | +47.95% |
| Q1 2018 | 2018-03-31 | $340,000 | −$135,000 | −28.42% |
| Q4 2017 | 2017-12-31 | $487,000 | −$24,000 | −4.70% |
| Q3 2017 | 2017-09-30 | $523,000 | $46,000 | +9.64% |
| Q2 2017 | 2017-06-30 | $438,000 | −$3,000 | −0.68% |
| Q1 2017 | 2017-03-31 | $475,000 | $17,000 | +3.71% |
| Q4 2016 | 2016-12-31 | $511,000 | $75,000 | +17.20% |
| Q3 2016 | 2016-09-30 | $477,000 | $48,000 | +11.19% |
| Q2 2016 | 2016-06-30 | $441,000 | −$18,000 | −3.92% |
| Q1 2016 | 2016-03-31 | $458,000 | $32,000 | +7.51% |
| Q4 2015 | 2015-12-31 | $436,000 | −$69,000 | −13.66% |
| Q3 2015 | 2015-09-30 | $429,000 | $286,000 | +200.00% |
| Q2 2015 | 2015-06-30 | $459,000 | $362,000 | +373.20% |
| Q1 2015 | 2015-03-31 | $426,000 | $399,000 | +1477.78% |
| Q4 2014 | 2014-12-31 | $505,000 | — | — |
| Q3 2014 | 2014-09-30 | $143,000 | — | — |
| Q2 2014 | 2014-06-30 | $97,000 | — | — |
| Q1 2014 | 2014-03-31 | $27,000 | — | — |
Ocular Therapeutix revenue growth trends
Over the last five reported fiscal years, revenue grew from $17.4M to $52.0M, a compound annual growth rate of 24.45%. Ocular Therapeutix's latest reported quarter, Q2 2026, generated $13.5M in revenue, an increase of 0.12% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Ocular Therapeutix source filings ↗